Escolar Documentos
Profissional Documentos
Cultura Documentos
Síndrome Metabólica:
Tratamento com Fibratos
1
Projeto Diretrizes
Associação Médica Brasileira e Conselho Federal de Medicina
OBJETIVO:
Fornecer recomendações para o tratamento com fibratos na síndrome metabólica.
CONFLITO DE INTERESSE:
Os conflitos de interesse declarados pelos participantes da elaboração desta
diretriz estão detalhados na página 4.
INTRODUÇÃO
13. Rubins HB, Robins SJ, Collins D, Fye CL, PPARgamma activators. Nature 1998;
Anderson JW, Elam MB, et al. Gemfibrozil 393:790–3.
for the secondary prevention of coronary
heart disease in men with low levels of high- 18. Dumont M, Mauriège P, Bergeron J,
density lipoprotein cholesterol. N Engl J Després JP, Prud’homme D. Effect of a six
Med 1999;341:410–8. month gemfibrozil treatment and dietary
recommendations on the metabolic risk
14. The Bezafibrate Infarction Prevention profile of visceral obese men. Int J Obes
(BIP) study group. Lipids and lipoproteins Relat Metab Disord 2001;25:1136–43.
in symptomatic coronary heart disease:
distribution, intercorrelations, and 19. Saku K, Gartside PS, Hynd BA, Kashyap
significance for risk classification in 6700 ML. Mechanisms of action of gemfibrozil
men and 1500 women. Circulation 1992; on lipoprotein metabolism. J Clin Invest
86:839–48. 1985;75:1702–12.
15. Frick MH, Syvanne M, Nieminen MS, 20. Ye JM, Doyle PJ, Iglesias MA, Watson DG,
Kauma H, Majahalme S, Virtanen V, et Cooney GJ, Kraegen EW. Peroxisome
al. Prevention of the angiographic proliferator-activated receptor (PPAR)-
progression of coronary and vein-graft alpha activation lowers muscle lipids and
atherosclerosis by gemfibrozil after coronary improves insulin sensitivity in high fat-fed
bypass surgery in men with low levels of rats: comparison with PPAR-gamma
HDL cholesterol. Circulation 1997; activation. Diabetes 2001;50:411–7.
96:2137-43.
21. Kobayashi M, Shigeta Y, Hirata Y, Omori Y,
16. Ericsson CG, Hamsten A, Nilsson J, Grip Sakamoto N, Nambu S, et al. Improvement
L, Svane B, de Faire U. Angiographic of glucose tolerance in NIDDM by clofibrate:
assessment of effects of bezafibrate on randomized double-blind study. Diabetes Care
progression of coronary artery disease in 1988;11:495–9.
young male post-infarction patients. Lancet
1996;347:849–53. 22. Mussoni L, Mannucci L, Sirtori C,
Pazzucconi F, Bonfardeci G, Cimminiello
17. Staels B, Koenig W, Habib A, Merval R, C, et al. Effects of gemfibrozil on insulin
Lebret M, Torra IP, et al. Activation of sensitivity and on haemostatic variables in
human aortic smooth-muscle cells is hypertriglyceridemic patients. Atheros-
inhibited by PPARalpha but not by clerosis 2000;148:397-406.